FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162077159> ?p ?o ?g. }

• W2162077159 endingPage "1467" @default.
• W2162077159 startingPage "1455" @default.
• W2162077159 abstract "Phosphodiesterase type-5 (PDE-5) inhibitors have previously been evaluated for their efficacy and safety in various clinical trials in men with erectile dysfunction (ED) with or without associated comorbidities.This is the first prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a PDE-5 inhibitor (i.e., vardenafil) in an exclusive population of men with ED and dyslipidemia.Three coprimary efficacy measurements (Sexual Encounter Performance [SEP]2, SEP3, International Index of Erectile Function-Erectile Function [IIEF-EF] domain scores) were used to assess the differential effect of vardenafil vs. placebo in this patient population. Adverse events (AEs) safety data were obtained to compare safety outcomes.This 12-week of randomized, double-blind, placebo-controlled study was conducted in 59 U.S. centers. Patients received either on-demand, flexible-dose vardenafil 10 mg (titrated to 5 mg or 20 mg based upon efficacy and safety) or placebo.Of the 712 patients screened and entered into the study, 395 were randomized. Baseline demographics for the intent-to-treat population included: mean age, 54.4 years (+/-7.5 standard deviation [SD]); 76% Caucasian; mean body mass index (BMI), 31.7 kg/m(2) (+/-12.7 SD); 47% past/present smoker; and 42% severe ED. Aside from dyslipidemia, other comorbidities included hypertension, 61%; obesity (i.e., BMI >/= 30), 51%; and type 1 or 2 diabetes, 40%. During the 12-week treatment period, the least squares (LS) adjusted mean success rates in patients on vardenafil vs. placebo were: SEP2, 79.09% vs. 51.92%; and SEP3, 66.69% vs. 33.83% (P < 0.001). The LS adjusted mean IIEF-EF domain score for week 12 using LOCF was 21.99 in patients on vardenafil therapy vs. 14.83 in those on placebo (P < 0.001). The most commonly encountered AEs were headache and nasal congestion.Vardenafil was demonstrated to be safe and effective for managing ED in men with ED and associated dyslipidemia. The results of this study support the role of expanded research on outcomes related to effective ED treatment and aggressive lipid control." @default.
• W2162077159 created "2016-06-24" @default.
• W2162077159 creator A5003281622 @default.
• W2162077159 creator A5007987589 @default.
• W2162077159 creator A5013180579 @default.
• W2162077159 creator A5030609617 @default.
• W2162077159 creator A5033940451 @default.
• W2162077159 creator A5068698993 @default.
• W2162077159 creator A5083479895 @default.
• W2162077159 creator A5091038906 @default.
• W2162077159 date "2008-06-01" @default.
• W2162077159 modified "2023-09-30" @default.
• W2162077159 title "Vardenafil in Men with Stable Statin Therapy and Dyslipidemia" @default.
• W2162077159 cites W1488659805 @default.
• W2162077159 cites W1515660899 @default.
• W2162077159 cites W1543887304 @default.
• W2162077159 cites W1555005471 @default.
• W2162077159 cites W1950745526 @default.
• W2162077159 cites W1958093676 @default.
• W2162077159 cites W1967069595 @default.
• W2162077159 cites W1973576121 @default.
• W2162077159 cites W1980593077 @default.
• W2162077159 cites W1982802657 @default.
• W2162077159 cites W1987747940 @default.
• W2162077159 cites W1999059326 @default.
• W2162077159 cites W2009682810 @default.
• W2162077159 cites W2010554796 @default.
• W2162077159 cites W2011962445 @default.
• W2162077159 cites W2019118830 @default.
• W2162077159 cites W2026664968 @default.
• W2162077159 cites W2028224074 @default.
• W2162077159 cites W2028673628 @default.
• W2162077159 cites W2033049068 @default.
• W2162077159 cites W2033209259 @default.
• W2162077159 cites W2035776427 @default.
• W2162077159 cites W2038393150 @default.
• W2162077159 cites W2038961111 @default.
• W2162077159 cites W2040942287 @default.
• W2162077159 cites W2044156754 @default.
• W2162077159 cites W2047042164 @default.
• W2162077159 cites W2048005308 @default.
• W2162077159 cites W2058314056 @default.
• W2162077159 cites W2060344709 @default.
• W2162077159 cites W2061953311 @default.
• W2162077159 cites W2063444548 @default.
• W2162077159 cites W2074563209 @default.
• W2162077159 cites W2076904876 @default.
• W2162077159 cites W2077642733 @default.
• W2162077159 cites W2088463213 @default.
• W2162077159 cites W2093237077 @default.
• W2162077159 cites W2095551096 @default.
• W2162077159 cites W2098993475 @default.
• W2162077159 cites W2099932408 @default.
• W2162077159 cites W2108164252 @default.
• W2162077159 cites W2111494287 @default.
• W2162077159 cites W2128868945 @default.
• W2162077159 cites W2135586734 @default.
• W2162077159 cites W2150494864 @default.
• W2162077159 cites W2156867396 @default.
• W2162077159 cites W2159383994 @default.
• W2162077159 cites W2297358297 @default.
• W2162077159 cites W2324677651 @default.
• W2162077159 cites W2338618266 @default.
• W2162077159 cites W2429760413 @default.
• W2162077159 cites W2468332851 @default.
• W2162077159 cites W2792073297 @default.
• W2162077159 cites W2914045858 @default.
• W2162077159 cites W4243770305 @default.
• W2162077159 cites W4253571104 @default.
• W2162077159 doi "https://doi.org/10.1111/j.1743-6109.2008.00820.x" @default.
• W2162077159 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18373526" @default.
• W2162077159 hasPublicationYear "2008" @default.
• W2162077159 type Work @default.
• W2162077159 sameAs 2162077159 @default.
• W2162077159 citedByCount "38" @default.
• W2162077159 countsByYear W21620771592012 @default.
• W2162077159 countsByYear W21620771592013 @default.
• W2162077159 countsByYear W21620771592014 @default.
• W2162077159 countsByYear W21620771592016 @default.
• W2162077159 countsByYear W21620771592017 @default.
• W2162077159 countsByYear W21620771592020 @default.
• W2162077159 crossrefType "journal-article" @default.
• W2162077159 hasAuthorship W2162077159A5003281622 @default.
• W2162077159 hasAuthorship W2162077159A5007987589 @default.
• W2162077159 hasAuthorship W2162077159A5013180579 @default.
• W2162077159 hasAuthorship W2162077159A5030609617 @default.
• W2162077159 hasAuthorship W2162077159A5033940451 @default.
• W2162077159 hasAuthorship W2162077159A5068698993 @default.
• W2162077159 hasAuthorship W2162077159A5083479895 @default.
• W2162077159 hasAuthorship W2162077159A5091038906 @default.
• W2162077159 hasConcept C126322002 @default.
• W2162077159 hasConcept C142724271 @default.
• W2162077159 hasConcept C168563851 @default.
• W2162077159 hasConcept C1862650 @default.
• W2162077159 hasConcept C197934379 @default.
• W2162077159 hasConcept C204787440 @default.
• W2162077159 hasConcept C27081682 @default.
• W2162077159 hasConcept C2775871022 @default.

• next